Support teaching, research, and patient care.
Principal Investigator and Director, PharmGKB/ClinPGx
Director/MPIClinPGx is a comprehensive pharmacogenomics (PGx) resource designed to (1) catalog, curate, annotate, integrate, generate and disseminate PGx knowledge, (2) advance PGx clinical implementation, (3) facilitate PGx integration with genomic medicine, and (4) promote PGx education. ClinPGx is formed from the integration of the NIH-funded PharmGKB, CPIC and PharmCAT projects, with plans for expanded content, new features and tools in the near future and in the long-term. This resource enables clinicians, laboratories, researchers and patients access to PGx information. ClinPGx is an affiliate grant of the Clinical Genome Resource
Palo Alto
Co-PI and DirectorPharmGKB is the premier pharmacogenomics knowledge resource: an online, freely available, human curated, NIH-funded resource that collects, curates and disseminates knowledge about the impact of human genetic variation on drug response, from basic research studies to clinical implementation.
CA
Informatics Co-Director, Steering CommitteeCPIC is an international consortium that create peer-reviewed, evidence-based clinical practice guidelines to facilitate use of pharmacogenetic tests for patient care. The Informatics group support the adoption of the CPIC guidelines by identifying and resolving potential technical barriers to guideline implementation within a clinical electronic environment.
Co-InvestigatorPharmCAT is a software tool that translates genetic test results to prescribing recommendations which can be used to inform treatment decisions.
Pharmacogenomics Working Group Co-ChairThe ClinGen Pharmacogenomics (PGx) Working Group is a multi-disciplinary team of researchers and professionals with expertise in pharmacogenomics, clinical pharmacology, medical genetics, and molecular diagnosis.
My work focuses on pharmacogenomics, the study of the impact of genetics on drug response, and its application to personalized medicine and personal genomics. My interests range from basic research studying gene-variant-drug associations to translation of pharmacogenomics information into the clinical setting, including reducing barriers to implementing PGx prescribing guidelines in the clinical electronic environment (CDS/EHR). I am particularly interested in translation of human genome sequencing data to pharmacogenomic-based therapeutic recommendations that are actionable in the clinic.
